Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil
Identifieur interne : 001D18 ( Istex/Corpus ); précédent : 001D17; suivant : 001D19Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil
Auteurs : Ulla M Rs ; Vladimir Tolmachev ; Anders SundinSource :
- Nuclear Medicine and Biology [ 0969-8051 ] ; 2000.
English descriptors
- KwdEn :
- Teeft :
- Acetic acid, Autoradiography, Bladder liver kidney muscle, Cancer patients, Clear delineation, Clinical immunology, Diagnostic modality, Diagnostic radiology, Elsevier science, High uptake, Human melanoma, Imaging, Larsson, Malignant melanoma, Melanin, Melanoma, Melanoma cells, Melanoma seeker, Melanoma tumors, Melanotic melanoma, Murine, Murine melanoma, Nascent melanin, Normal tissues, Nucl, Ocular melanoma, Other tissues, Overall concentration, Phosphate buffer, Pigment cell, Positron emission tomography, Preformed melanin, Present study, Previous autoradiographic studies, Radioactivity, Radioactivity concentrations, Relative concentration, Selective accumulation, Selective incorporation, Selective uptake, Sodium metabisulphite, Subcutaneous melanoma, Thiouracil, Tracer, Uppsala, Uppsala university.
Abstract
Abstract: Positron emission tomography (PET) has evolved as a new diagnostic modality in cancer patients. Thioureylenes, such as thiouracil and methimazole, are known to be incorporated into growing melanin and selectively retained in melanotic melanoma. In the present study we used [76Br]5-bromo-2-thiouracil as tracer for PET imaging of human and murine melanotic melanoma transplanted subcutaneously into rats. The melanomas were clearly depicted 1 day after the injection, when [76Br]5-bromo-2-thiouracil was retained in the tumors though the overall radioactivity concentration in the body had declined. Accumulation of 76Br was also seen in bladder, liver, and kidney. In addition, the rats were simultaneously injected with [125I]5-iodo-2-thiouracil and the tissue distribution of radioactivity was mapped by whole-body autoradiography. The results confirmed the selective uptake of thiouracil in the melanoma where the concentration of 125I-radioactivity was about three-fold higher than that in the liver and lungs. These results show the possibility of using [76Br]5-bromo-2-thiouracil for PET diagnostics of melanoma, including dosimetry, prior to targeted therapy using [131I]5-iodo-2-thiouracil or [211At]5-astato-2-thiouracil.
Url:
DOI: 10.1016/S0969-8051(00)00147-5
Links to Exploration step
ISTEX:71278FD93BB5B13566B59F3807739BFA73A2B762Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil</title><author><name sortKey="M Rs, Ulla" sort="M Rs, Ulla" uniqKey="M Rs U" first="Ulla" last="M Rs">Ulla M Rs</name><affiliation><mods:affiliation>E-mail: Ulla.Mars@tox.uu.se</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Tolmachev, Vladimir" sort="Tolmachev, Vladimir" uniqKey="Tolmachev V" first="Vladimir" last="Tolmachev">Vladimir Tolmachev</name><affiliation><mods:affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Sundin, Anders" sort="Sundin, Anders" uniqKey="Sundin A" first="Anders" last="Sundin">Anders Sundin</name><affiliation><mods:affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Diagnostic Radiology and Uppsala University PETcentre, Uppsala University, Uppsala, Sweden</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:71278FD93BB5B13566B59F3807739BFA73A2B762</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0969-8051(00)00147-5</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-WP2NN2FT-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001D18</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001D18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil</title><author><name sortKey="M Rs, Ulla" sort="M Rs, Ulla" uniqKey="M Rs U" first="Ulla" last="M Rs">Ulla M Rs</name><affiliation><mods:affiliation>E-mail: Ulla.Mars@tox.uu.se</mods:affiliation></affiliation><affiliation><mods:affiliation>Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Tolmachev, Vladimir" sort="Tolmachev, Vladimir" uniqKey="Tolmachev V" first="Vladimir" last="Tolmachev">Vladimir Tolmachev</name><affiliation><mods:affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden</mods:affiliation></affiliation></author><author><name sortKey="Sundin, Anders" sort="Sundin, Anders" uniqKey="Sundin A" first="Anders" last="Sundin">Anders Sundin</name><affiliation><mods:affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Diagnostic Radiology and Uppsala University PETcentre, Uppsala University, Uppsala, Sweden</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Nuclear Medicine and Biology</title><title level="j" type="abbrev">NMB</title><idno type="ISSN">0969-8051</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">27</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="845">845</biblScope><biblScope unit="page" to="849">849</biblScope></imprint><idno type="ISSN">0969-8051</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0969-8051</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>76Br</term><term>Autoradiography</term><term>Melanin</term><term>Melanoma</term><term>PET</term><term>Thiouracil</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acetic acid</term><term>Autoradiography</term><term>Bladder liver kidney muscle</term><term>Cancer patients</term><term>Clear delineation</term><term>Clinical immunology</term><term>Diagnostic modality</term><term>Diagnostic radiology</term><term>Elsevier science</term><term>High uptake</term><term>Human melanoma</term><term>Imaging</term><term>Larsson</term><term>Malignant melanoma</term><term>Melanin</term><term>Melanoma</term><term>Melanoma cells</term><term>Melanoma seeker</term><term>Melanoma tumors</term><term>Melanotic melanoma</term><term>Murine</term><term>Murine melanoma</term><term>Nascent melanin</term><term>Normal tissues</term><term>Nucl</term><term>Ocular melanoma</term><term>Other tissues</term><term>Overall concentration</term><term>Phosphate buffer</term><term>Pigment cell</term><term>Positron emission tomography</term><term>Preformed melanin</term><term>Present study</term><term>Previous autoradiographic studies</term><term>Radioactivity</term><term>Radioactivity concentrations</term><term>Relative concentration</term><term>Selective accumulation</term><term>Selective incorporation</term><term>Selective uptake</term><term>Sodium metabisulphite</term><term>Subcutaneous melanoma</term><term>Thiouracil</term><term>Tracer</term><term>Uppsala</term><term>Uppsala university</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Positron emission tomography (PET) has evolved as a new diagnostic modality in cancer patients. Thioureylenes, such as thiouracil and methimazole, are known to be incorporated into growing melanin and selectively retained in melanotic melanoma. In the present study we used [76Br]5-bromo-2-thiouracil as tracer for PET imaging of human and murine melanotic melanoma transplanted subcutaneously into rats. The melanomas were clearly depicted 1 day after the injection, when [76Br]5-bromo-2-thiouracil was retained in the tumors though the overall radioactivity concentration in the body had declined. Accumulation of 76Br was also seen in bladder, liver, and kidney. In addition, the rats were simultaneously injected with [125I]5-iodo-2-thiouracil and the tissue distribution of radioactivity was mapped by whole-body autoradiography. The results confirmed the selective uptake of thiouracil in the melanoma where the concentration of 125I-radioactivity was about three-fold higher than that in the liver and lungs. These results show the possibility of using [76Br]5-bromo-2-thiouracil for PET diagnostics of melanoma, including dosimetry, prior to targeted therapy using [131I]5-iodo-2-thiouracil or [211At]5-astato-2-thiouracil.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>melanoma</json:string><json:string>melanin</json:string><json:string>murine</json:string><json:string>larsson</json:string><json:string>autoradiography</json:string><json:string>uppsala</json:string><json:string>tracer</json:string><json:string>nucl</json:string><json:string>positron emission tomography</json:string><json:string>selective incorporation</json:string><json:string>acetic acid</json:string><json:string>imaging</json:string><json:string>thiouracil</json:string><json:string>radioactivity</json:string><json:string>melanotic melanoma</json:string><json:string>malignant melanoma</json:string><json:string>nascent melanin</json:string><json:string>selective accumulation</json:string><json:string>selective uptake</json:string><json:string>phosphate buffer</json:string><json:string>uppsala university</json:string><json:string>overall concentration</json:string><json:string>diagnostic radiology</json:string><json:string>other tissues</json:string><json:string>previous autoradiographic studies</json:string><json:string>murine melanoma</json:string><json:string>elsevier science</json:string><json:string>sodium metabisulphite</json:string><json:string>clinical immunology</json:string><json:string>subcutaneous melanoma</json:string><json:string>bladder liver kidney muscle</json:string><json:string>high uptake</json:string><json:string>human melanoma</json:string><json:string>relative concentration</json:string><json:string>melanoma tumors</json:string><json:string>normal tissues</json:string><json:string>clear delineation</json:string><json:string>diagnostic modality</json:string><json:string>present study</json:string><json:string>radioactivity concentrations</json:string><json:string>cancer patients</json:string><json:string>ocular melanoma</json:string><json:string>preformed melanin</json:string><json:string>melanoma cells</json:string><json:string>melanoma seeker</json:string><json:string>pigment cell</json:string></teeft></keywords><author><json:item><name>Ulla Mårs</name><affiliations><json:string>E-mail: Ulla.Mars@tox.uu.se</json:string><json:string>Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, Uppsala, Sweden</json:string></affiliations></json:item><json:item><name>Vladimir Tolmachev</name><affiliations><json:string>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden</json:string></affiliations></json:item><json:item><name>Anders Sundin</name><affiliations><json:string>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Diagnostic Radiology and Uppsala University PETcentre, Uppsala University, Uppsala, Sweden</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Melanin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Melanoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>PET</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Thiouracil</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Autoradiography</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>76Br</value></json:item></subject><arkIstex>ark:/67375/6H6-WP2NN2FT-9</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: Positron emission tomography (PET) has evolved as a new diagnostic modality in cancer patients. Thioureylenes, such as thiouracil and methimazole, are known to be incorporated into growing melanin and selectively retained in melanotic melanoma. In the present study we used [76Br]5-bromo-2-thiouracil as tracer for PET imaging of human and murine melanotic melanoma transplanted subcutaneously into rats. The melanomas were clearly depicted 1 day after the injection, when [76Br]5-bromo-2-thiouracil was retained in the tumors though the overall radioactivity concentration in the body had declined. Accumulation of 76Br was also seen in bladder, liver, and kidney. In addition, the rats were simultaneously injected with [125I]5-iodo-2-thiouracil and the tissue distribution of radioactivity was mapped by whole-body autoradiography. The results confirmed the selective uptake of thiouracil in the melanoma where the concentration of 125I-radioactivity was about three-fold higher than that in the liver and lungs. These results show the possibility of using [76Br]5-bromo-2-thiouracil for PET diagnostics of melanoma, including dosimetry, prior to targeted therapy using [131I]5-iodo-2-thiouracil or [211At]5-astato-2-thiouracil.</abstract><qualityIndicators><score>7.218</score><pdfWordCount>3238</pdfWordCount><pdfCharCount>20860</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>596 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>165</abstractWordCount><abstractCharCount>1241</abstractCharCount><keywordCount>6</keywordCount></qualityIndicators><title>Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil</title><pmid><json:string>11150719</json:string></pmid><pii><json:string>S0969-8051(00)00147-5</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Nuclear Medicine and Biology</title><language><json:string>unknown</json:string></language><publicationDate>2000</publicationDate><issn><json:string>0969-8051</json:string></issn><pii><json:string>S0969-8051(00)X0047-9</json:string></pii><volume>27</volume><issue>8</issue><pages><first>845</first><last>849</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>35S</json:string></date><geogName></geogName><orgName><json:string>Sigma Chemical Company</json:string><json:string>DEPARTMENT OF DIAGNOSTIC RADIOLOGY, ONCOLOGY AND CLINICAL IMMUNOLOGY, DIVISION OF DIAGNOSTIC RADIOLOGY AND UPPSALA UNIVERSITY PETCENTRE, UPPSALA UNIVERSITY, UPPSALA, SWEDEN ABSTRACT</json:string><json:string>Uppsala University</json:string><json:string>Pharmacia</json:string><json:string>Elsevier Science Inc.</json:string><json:string>AG</json:string><json:string>Organic Chemistry Department, Uppsala University</json:string><json:string>DEPARTMENT OF DIAGNOSTIC RADIOLOGY, ONCOLOGY AND CLINICAL IMMUNOLOGY, DIVISION OF BIOMEDICAL RADIATION SCIENCES, AND</json:string><json:string>DEPARTMENT OF PHARMACEUTICAL BIOSCIENCES, DIVISION OF TOXICOLOGY</json:string><json:string>Division of Toxicology</json:string><json:string>Swedish Cancer Society (grant no. 3973-B97-01XAB)</json:string></orgName><orgName_funder><json:string>Swedish Cancer Society (grant no. 3973-B97-01XAB)</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Johanna Sundin</json:string><json:string>Bengt</json:string><json:string>Anders Sundin</json:string><json:string>Karl-Johan Fasth</json:string><json:string>S. Larsson</json:string><json:string>U. Mårs</json:string><json:string>Kiyoshi Yamada</json:string><json:string>Anna Orlova</json:string></persName><placeName><json:string>Lund</json:string><json:string>Uppsala</json:string><json:string>Switzerland</json:string><json:string>Basel</json:string><json:string>Sweden</json:string><json:string>Belgium</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Barret et al.</json:string><json:string>U. Mårs et al.</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-WP2NN2FT-9</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - radiology, nuclear medicine & medical imaging</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - nuclear medicine & medical imaging</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Cancer Research</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Radiology Nuclear Medicine and imaging</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string><json:string>4 - endocrinopathies</json:string></inist></categories><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S0969-8051(00)00147-5</json:string></doi><id>71278FD93BB5B13566B59F3807739BFA73A2B762</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WP2NN2FT-9/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WP2NN2FT-9/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-WP2NN2FT-9/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>©2000 Elsevier Science Inc.</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</p></availability><date>2000</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note type="content">FIG. 1: (Left) An axial PET image of a rat showing high uptake of [76Br]5-bromo-2-thiouracil in a murine melanoma of 8 cc on the left hind leg (long arrow) and a slightly lower uptake in a human melanoma of 1 cc on the right hind leg (short arrow) 1 day after the IV injection. (Right) The corresponding coronary image is shown.</note><note type="content">TABLE 1: Uptake of [76Br]5-bromo-2-Thiouracil (SUV) in Subcutaneous Melanoma in Rats Studied by PETlegend</note><note type="content">TABLE 2: Uptake of [125I] 5-Bromo-2-Thiouracil in Melanoma in Rats Studied by Whole-Body Autoradiography and Computer-Based Image Analysislegend</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil</title><author xml:id="author-0000"><persName><forename type="first">Ulla</forename><surname>Mårs</surname></persName><email>Ulla.Mars@tox.uu.se</email><affiliation>Address correspondence to: Dr. U. Mårs, Uppsala University, Division of Toxicology, Box 594, SE-751 24 Uppsala, Sweden</affiliation><affiliation>Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, Uppsala, Sweden</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Vladimir</forename><surname>Tolmachev</surname></persName><affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Anders</forename><surname>Sundin</surname></persName><affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Diagnostic Radiology and Uppsala University PETcentre, Uppsala University, Uppsala, Sweden</affiliation></author><idno type="istex">71278FD93BB5B13566B59F3807739BFA73A2B762</idno><idno type="ark">ark:/67375/6H6-WP2NN2FT-9</idno><idno type="DOI">10.1016/S0969-8051(00)00147-5</idno><idno type="PII">S0969-8051(00)00147-5</idno></analytic><monogr><title level="j">Nuclear Medicine and Biology</title><title level="j" type="abbrev">NMB</title><idno type="pISSN">0969-8051</idno><idno type="PII">S0969-8051(00)X0047-9</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000"></date><biblScope unit="volume">27</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="845">845</biblScope><biblScope unit="page" to="849">849</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Positron emission tomography (PET) has evolved as a new diagnostic modality in cancer patients. Thioureylenes, such as thiouracil and methimazole, are known to be incorporated into growing melanin and selectively retained in melanotic melanoma. In the present study we used [76Br]5-bromo-2-thiouracil as tracer for PET imaging of human and murine melanotic melanoma transplanted subcutaneously into rats. The melanomas were clearly depicted 1 day after the injection, when [76Br]5-bromo-2-thiouracil was retained in the tumors though the overall radioactivity concentration in the body had declined. Accumulation of 76Br was also seen in bladder, liver, and kidney. In addition, the rats were simultaneously injected with [125I]5-iodo-2-thiouracil and the tissue distribution of radioactivity was mapped by whole-body autoradiography. The results confirmed the selective uptake of thiouracil in the melanoma where the concentration of 125I-radioactivity was about three-fold higher than that in the liver and lungs. These results show the possibility of using [76Br]5-bromo-2-thiouracil for PET diagnostics of melanoma, including dosimetry, prior to targeted therapy using [131I]5-iodo-2-thiouracil or [211At]5-astato-2-thiouracil.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Melanin</term></item><item><term>Melanoma</term></item><item><term>PET</term></item><item><term>Thiouracil</term></item><item><term>Autoradiography</term></item><item><term>76Br</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2000">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WP2NN2FT-9/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"><istex:entity SYSTEM="gr1" NDATA="IMAGE" name="GR1"></istex:entity></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla" xml:lang="en"><item-info><jid>NMB</jid><aid>5510</aid><ce:pii>S0969-8051(00)00147-5</ce:pii><ce:doi>10.1016/S0969-8051(00)00147-5</ce:doi><ce:copyright type="full-transfer" year="2000">Elsevier Science Inc.</ce:copyright></item-info><head><ce:title>Positron emission tomography of experimental melanoma with [<ce:sup>76</ce:sup>Br]5-bromo-2-thiouracil</ce:title><ce:author-group><ce:author><ce:indexed-name>Mars</ce:indexed-name><ce:given-name>Ulla</ce:given-name><ce:surname>Mårs</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref><ce:cross-ref refid="CORR1">*</ce:cross-ref><ce:e-address>Ulla.Mars@tox.uu.se</ce:e-address></ce:author><ce:author><ce:given-name>Vladimir</ce:given-name><ce:surname>Tolmachev</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Anders</ce:given-name><ce:surname>Sundin</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>1</ce:label><ce:textfn>Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, Uppsala, Sweden</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>2</ce:label><ce:textfn>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>3</ce:label><ce:textfn>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Diagnostic Radiology and Uppsala University PETcentre, Uppsala University, Uppsala, Sweden</ce:textfn></ce:affiliation><ce:correspondence id="CORR1"><ce:label>*</ce:label><ce:text>Address correspondence to: Dr. U. Mårs, Uppsala University, Division of Toxicology, Box 594, SE-751 24 Uppsala, Sweden</ce:text></ce:correspondence></ce:author-group><ce:date-received day="30" month="1" year="2000"></ce:date-received><ce:date-accepted day="30" month="5" year="2000"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Positron emission tomography (PET) has evolved as a new diagnostic modality in cancer patients. Thioureylenes, such as thiouracil and methimazole, are known to be incorporated into growing melanin and selectively retained in melanotic melanoma. In the present study we used [<ce:sup>76</ce:sup>Br]5-bromo-2-thiouracil as tracer for PET imaging of human and murine melanotic melanoma transplanted subcutaneously into rats. The melanomas were clearly depicted 1 day after the injection, when [<ce:sup>76</ce:sup>Br]5-bromo-2-thiouracil was retained in the tumors though the overall radioactivity concentration in the body had declined. Accumulation of <ce:sup>76</ce:sup>Br was also seen in bladder, liver, and kidney. In addition, the rats were simultaneously injected with [<ce:sup>125</ce:sup>I]5-iodo-2-thiouracil and the tissue distribution of radioactivity was mapped by whole-body autoradiography. The results confirmed the selective uptake of thiouracil in the melanoma where the concentration of <ce:sup>125</ce:sup>I-radioactivity was about three-fold higher than that in the liver and lungs. These results show the possibility of using [<ce:sup>76</ce:sup>Br]5-bromo-2-thiouracil for PET diagnostics of melanoma, including dosimetry, prior to targeted therapy using [<ce:sup>131</ce:sup>I]5-iodo-2-thiouracil or [<ce:sup>211</ce:sup>At]5-astato-2-thiouracil.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Melanin</ce:text></ce:keyword><ce:keyword><ce:text>Melanoma</ce:text></ce:keyword><ce:keyword><ce:text>PET</ce:text></ce:keyword><ce:keyword><ce:text>Thiouracil</ce:text></ce:keyword><ce:keyword><ce:text>Autoradiography</ce:text></ce:keyword><ce:keyword><ce:text><ce:sup>76</ce:sup>Br</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Positron emission tomography of experimental melanoma with [</title></titleInfo><name type="personal"><namePart type="given">Ulla</namePart><namePart type="family">Mårs</namePart><affiliation>E-mail: Ulla.Mars@tox.uu.se</affiliation><affiliation>Department of Pharmaceutical Biosciences, Division of Toxicology, Uppsala University, Uppsala, Sweden</affiliation><description>Address correspondence to: Dr. U. Mårs, Uppsala University, Division of Toxicology, Box 594, SE-751 24 Uppsala, Sweden</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vladimir</namePart><namePart type="family">Tolmachev</namePart><affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anders</namePart><namePart type="family">Sundin</namePart><affiliation>Department of Diagnostic Radiology, Oncology and Clinical Immunology, Division of Diagnostic Radiology and Uppsala University PETcentre, Uppsala University, Uppsala, Sweden</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Positron emission tomography (PET) has evolved as a new diagnostic modality in cancer patients. Thioureylenes, such as thiouracil and methimazole, are known to be incorporated into growing melanin and selectively retained in melanotic melanoma. In the present study we used [76Br]5-bromo-2-thiouracil as tracer for PET imaging of human and murine melanotic melanoma transplanted subcutaneously into rats. The melanomas were clearly depicted 1 day after the injection, when [76Br]5-bromo-2-thiouracil was retained in the tumors though the overall radioactivity concentration in the body had declined. Accumulation of 76Br was also seen in bladder, liver, and kidney. In addition, the rats were simultaneously injected with [125I]5-iodo-2-thiouracil and the tissue distribution of radioactivity was mapped by whole-body autoradiography. The results confirmed the selective uptake of thiouracil in the melanoma where the concentration of 125I-radioactivity was about three-fold higher than that in the liver and lungs. These results show the possibility of using [76Br]5-bromo-2-thiouracil for PET diagnostics of melanoma, including dosimetry, prior to targeted therapy using [131I]5-iodo-2-thiouracil or [211At]5-astato-2-thiouracil.</abstract><note type="content">FIG. 1: (Left) An axial PET image of a rat showing high uptake of [76Br]5-bromo-2-thiouracil in a murine melanoma of 8 cc on the left hind leg (long arrow) and a slightly lower uptake in a human melanoma of 1 cc on the right hind leg (short arrow) 1 day after the IV injection. (Right) The corresponding coronary image is shown.</note><note type="content">TABLE 1: Uptake of [76Br]5-bromo-2-Thiouracil (SUV) in Subcutaneous Melanoma in Rats Studied by PETlegend</note><note type="content">TABLE 2: Uptake of [125I] 5-Bromo-2-Thiouracil in Melanoma in Rats Studied by Whole-Body Autoradiography and Computer-Based Image Analysislegend</note><subject lang="en"><genre>Keywords</genre><topic>Melanin</topic><topic>Melanoma</topic><topic>PET</topic><topic>Thiouracil</topic><topic>Autoradiography</topic><topic>76Br</topic></subject><relatedItem type="host"><titleInfo><title>Nuclear Medicine and Biology</title></titleInfo><titleInfo type="abbreviated"><title>NMB</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued></originInfo><identifier type="ISSN">0969-8051</identifier><identifier type="PII">S0969-8051(00)X0047-9</identifier><part><date>2000</date><detail type="volume"><number>27</number><caption>vol.</caption></detail><detail type="issue"><number>8</number><caption>no.</caption></detail><extent unit="issue-pages"><start>693</start><end>872</end></extent><extent unit="pages"><start>845</start><end>849</end></extent></part></relatedItem><identifier type="istex">71278FD93BB5B13566B59F3807739BFA73A2B762</identifier><identifier type="ark">ark:/67375/6H6-WP2NN2FT-9</identifier><identifier type="DOI">10.1016/S0969-8051(00)00147-5</identifier><identifier type="PII">S0969-8051(00)00147-5</identifier><accessCondition type="use and reproduction" contentType="copyright">©2000 Elsevier Science Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>Elsevier Science Inc., ©2000</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-WP2NN2FT-9/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001D18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:71278FD93BB5B13566B59F3807739BFA73A2B762
|texte= Positron emission tomography of experimental melanoma with [76Br]5-bromo-2-thiouracil
}}
| This area was generated with Dilib version V0.6.33. |  |